Plasma cell leukemia: three case-reports and review of literature

Eddou, Hicham; Mahtat, El Mehdi; Zahid, Hamid; Maaroufi, Hicham El; Jennane, Selim; Messaoudi, N.; Doghmi, Kamal; Mikdame, M.

doi:10.1684/abc.2013.0888

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although PCL is defined by a blood plasma count greater than 2 G/l or a plasma cell count greater than 20% of leukocytes, recent studies have advocated the use of a lower threshold of CPC to define PCL [3][4][5].…”

Section: Discussionmentioning

confidence: 99%

Secondary plasma cell leukemia: Case report

Bounani¹,

Idrissi²,

Tarmidi³

et al. 2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder characterized by monoclonal proliferation of plasma cells in marrow and peripheral blood. It is defined by a blood plasma count greater than 2 G/l or a plasma cell count greater than 20% of white blood cells. There are two forms of PCL: primary PCL (primary plasma cell leukemia or PCL-P), which occurs de novo and is diagnosed by blood dissemination, and secondary PCL (secondary plasma cell leukemia or SPL), which is the result of the evolution of multiple myeloma (MM). We report an observation of secondary plasma cell leukemia in a 42-year-old female patient diagnosed at the hematology laboratory of the Mohamed VI University Hospital in Marrakech. The patient was being followed up for chronic end-stage renal failure in whom the etiological assessment of a hypercalcemia of fortuitous discovery revealed MM for which she was put on chemotherapy according to the Velcade-Thalidomide-Dexamethasone protocol with a good evolution after 6 courses. Two and a half years later, the patient presented with anemia and spinal pain. The biological work-up showed a normocytic normochromic anemia at 5.4 g/dl and hypercalcemia at 150 mg/l. The blood smear showed the presence of 22% of circulating plasma cells, the majority of which were dystrophic, in favor of secondary plasma cell leukemia. Patients diagnosed with multiple myeloma who have undergone treatment and have a stable disease should have regular surveillance, hence the interest of the blood smear examination in all multiple myeloma.

show abstract

Section: Discussionmentioning

confidence: 99%

Secondary plasma cell leukemia: Case report

Bounani¹,

Idrissi²,

Tarmidi³

et al. 2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

show abstract

“…The incidence of PCL in patients with MM is 2-4% and it accounts for 0.3% of leukemias. Extramedullary involvement is more common in pPCL as compared to PCL secondary to MM [4][5][6][7].…”

Section: Discussionmentioning

confidence: 99%

Secondary Plasma Cell Leukemia: A Case Report

Swaminathan

Váradi

2020

Cureus

View full text Add to dashboard Cite

Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma and has a poor prognosis. It needs prompt recognition in order to institute timely treatment. Given its relatively low incidence, it is an evolving area of research as well. This case report describes a patient with PCL in the setting of a previously treated myeloma. The report also reviews the clinicopathologic, cytogenetic, and immunophenotypic characteristics of PCL and its management.

show abstract

Plasma cell leukemia: Clinicopathologic, immunophenotypic and cytogenetic characteristics of 4 cases

AlGhasham

Alnounou

Alzahrani

et al. 2015

Hematology/Oncology and Stem Cell Therapy

View full text Add to dashboard Cite

Plasma cell leukemia (PCL) is a rare hematologic malignancy with very poor outcome. It is defined by the presence of >2 × 10(9)/L plasma cells or >20% plasmacytosis of the differential white cell count in the peripheral blood. Primary PCL is first diagnosed in the leukemic phase, while secondary PCL corresponds to the leukemic transformation of a previously diagnosed multiple myeloma (MM). The incidence of PCL ranges between 2-4% of patients with MM and 0.9% of patients with acute leukemia. In this case series, we describe the clinicopathologic, immunophenotypic, and cytogenetic findings of four patients diagnosed with PCL within a ten-year period (2002-2012) at King Faisal Specialist Hospital and Research Centre (General Organization), Riyadh, Saudi Arabia.

show abstract

Plasma cell leukemia: three case-reports and review of literature

Cited by 4 publications

References 0 publications

Secondary plasma cell leukemia: Case report

Secondary plasma cell leukemia: Case report

Secondary Plasma Cell Leukemia: A Case Report

Plasma cell leukemia: Clinicopathologic, immunophenotypic and cytogenetic characteristics of 4 cases

Contact Info

Product

Resources

About